122 related articles for article (PubMed ID: 2679069)
1. Congenital antithrombin III deficiency: insights into the pathogenesis of the hypercoagulable state and its management using markers of hemostatic system activation.
Bauer KA; Rosenberg RD
Am J Med; 1989 Sep; 87(3B):39S-43S. PubMed ID: 2679069
[TBL] [Abstract][Full Text] [Related]
2. Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency.
Bauer KA; Goodman TL; Kass BL; Rosenberg RD
J Clin Invest; 1985 Aug; 76(2):826-36. PubMed ID: 3875633
[TBL] [Abstract][Full Text] [Related]
3. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation.
Bauer KA; Rosenberg RD
Blood; 1987 Aug; 70(2):343-50. PubMed ID: 3607275
[TBL] [Abstract][Full Text] [Related]
4. Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses.
Conway EM; Bauer KA; Barzegar S; Rosenberg RD
J Clin Invest; 1987 Dec; 80(6):1535-44. PubMed ID: 3680513
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group.
Schwartz RS; Bauer KA; Rosenberg RD; Kavanaugh EJ; Davies DC; Bogdanoff DA
Am J Med; 1989 Sep; 87(3B):53S-60S. PubMed ID: 2679072
[TBL] [Abstract][Full Text] [Related]
6. Transfusion studies in patients with familial antithrombin III (ATIII) deficiency: half-disappearance time of infused ATIII and influence of such infusion on platelet life-span.
Winter JH; Fenech A; Bennett B; Douglas AS
Br J Haematol; 1981 Nov; 49(3):449-53. PubMed ID: 7295588
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of antithrombin III deficiency in blood donors selected for personal or familial history of venous thrombosis.
Finazzi G; Radice E; Armato A; Barbui T
Ric Clin Lab; 1985; 15(2):173-6. PubMed ID: 4059797
[TBL] [Abstract][Full Text] [Related]
8. Measurement of factor Xa-antithrombin III in plasma: relationship to prothrombin activation in vivo.
Gouin-Thibault I; Dewar L; Kulczycky M; Sternbach M; Ofosu FA
Br J Haematol; 1995 Jul; 90(3):669-80. PubMed ID: 7647008
[TBL] [Abstract][Full Text] [Related]
9. Congenital antithrombin III deficiency. Incidence and clinical features.
Hirsh J; Piovella F; Pini M
Am J Med; 1989 Sep; 87(3B):34S-38S. PubMed ID: 2679068
[TBL] [Abstract][Full Text] [Related]
10. Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate.
Büller HR; ten Cate JW
Am J Med; 1989 Sep; 87(3B):44S-48S. PubMed ID: 2679070
[TBL] [Abstract][Full Text] [Related]
11. Effective prophylaxis of thrombosis by antithrombin III concentrate in a pregnant woman with congenital antithrombin III deficiency: relations between plasma antithrombin III activity and the plasma levels of hemostatic molecular markers.
Inomoto T; Takamoto M; Tamura R; Maegawa M; Kamada M; Takayanagi M
Haemostasis; 1991; 21(3):147-54. PubMed ID: 1773985
[TBL] [Abstract][Full Text] [Related]
12. [Perioperative management for transurethral resection of bladder tumor (TUR-Bt) associated with congenital antithrombin III deficiency].
Mizuno J; Kato S; Namai S; Komiya Y; Kuwana Y; Morita S
Masui; 2009 Dec; 58(12):1524-7. PubMed ID: 20055199
[TBL] [Abstract][Full Text] [Related]
13. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency.
Bauer KA; Broekmans AW; Bertina RM; Conard J; Horellou MH; Samama MM; Rosenberg RD
Blood; 1988 May; 71(5):1418-26. PubMed ID: 2965928
[TBL] [Abstract][Full Text] [Related]
14. Familial antithrombin III deficiency.
Winter JH; Fenech A; Ridley W; Bennett B; Cumming AM; Mackie M; Douglas AS
Q J Med; 1982; 51(204):373-95. PubMed ID: 7156320
[TBL] [Abstract][Full Text] [Related]
15. [Perioperative management of congenital antithrombin III deficiency].
Shichino T; Omatsu Y
Masui; 1989 Dec; 38(12):1638-40. PubMed ID: 2614891
[TBL] [Abstract][Full Text] [Related]
16. Antithrombin III prophylaxis of venous thromboembolic disease after total hip or total knee replacement.
Francis CW; Pellegrini VD; Harris CM; Marder VJ
Am J Med; 1989 Sep; 87(3B):61S-66S. PubMed ID: 2478015
[TBL] [Abstract][Full Text] [Related]
17. Oxymetholone therapy in patients with familial antithrombin III deficiency.
Shibuya A; Ninomiya H; Nakazawa M; Nagasawa T; Yoda Y; Abe T
Thromb Haemost; 1988 Dec; 60(3):495-7. PubMed ID: 3238652
[TBL] [Abstract][Full Text] [Related]
18. Treatment of venous thrombosis in antithrombin III deficient patients with concentrates of antithrombin III.
Winter JH; Fenech A; Mackie M; Bennett B; Douglas AS
Clin Lab Haematol; 1982; 4(2):101-8. PubMed ID: 7116792
[TBL] [Abstract][Full Text] [Related]
19. [Antithrombin III. Physiologic, physiopathologic and laboratory aspects].
de Sousa JC; Ferreira R; Carriço F; Nunes V; Geraldes MJ; Parreira F; Ribeiro C
Rev Port Cardiol; 1991 Sep; 10(9):693-9. PubMed ID: 1747261
[TBL] [Abstract][Full Text] [Related]
20. Familial thrombosis: inherited deficiency of antithrombin III.
Mackie M; Bennett B; Ogston D; Douglas AS
Br Med J; 1978 Jan; 1(6106):136-8. PubMed ID: 620225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
